ArticleBMC cancer2021

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.

Xinghao Ai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.